<unk> , sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic,<unk>  was approved or authorized for emergency use to treat COVID‑19 in numerous countries.<unk>  was originally developed to treat hepatitis C, and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID‑19.<unk>  is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The most common side effect in healthy volunteers is raised blood levels of liver enzymes. The most common side effect in people with COVID‑19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Remdesivir
Coronavir
Entecavir
Saquinavir
Letermovir
Odalasvir
Maribavir
Fostemsavir